

# Genotyping: Ask The Experts

## 2018 BCA IRL Meeting

---

Michael Schanen, MLS<sup>CM</sup> (ASCP) SBB<sup>CM</sup>

Director, Immunohematology and Transfusion Services

---

# What does serology offer

Proven method, well integrated in the laboratory

Fast and available

Automated platforms adopted within the field

Abundance of expertise in the field

# What Challenges do Serologists encounter?

Multiple antibodies making it difficult to identify the unknown(s)

Weak reactive antibodies that don't follow the rules

Autoantibody vs. Alloantibody

Limitations of the methods: Recent Transfusion/Positive DAT

Limited by available reagents

**TAT: Patient in need of blood: How can we speed up the process**

# Case Review: Multiple Antibody Approach

Previous History of anti-E

**Genotype was performed on prior admission**

## Predicted Phenotype:

- C-E-c+e+                      Lu(a-b+)
- K-k+ Kp(a-b+) Js(a-b+)      Do(a-b+)
- Fy(a+b+)                        M+N+S-s+
- Jk(a+b-)

**Lets take a look at the panel with the Genotype**

**information we already know!**

# Case Review: Multiple Antibody Approach

	Rh						MNS				LU		P	Lewis		Kell		Duffy		Kidd		PEG
	D	C	E	c	e	f	M	N	S	s	Lu <sup>a</sup>	Lu <sup>b</sup>	P <sub>1</sub>	Le <sup>a</sup>	Le <sup>b</sup>	K	k	Fy <sup>a</sup>	Fy <sup>b</sup>	Jk <sup>a</sup>	Jk <sup>b</sup>	IAT
1) R <sub>1</sub> R <sub>1</sub>	+	+	0	0	+	0	+	+	+	+	0	+	+	+	0	0	+	+	0	0	+	3
2) rr	0	0	0	+	+	+	+	+	+	0	0	+	0	0	+	+	+	+	+	+	0	4
3) r <sup>r</sup> r	0	0	+	+	+	+	+	0	+	+	0	+	+	0	+	0	+	0	+	0	+	4
4) R <sub>1</sub> R <sub>1</sub>	+	+	0	0	+	0	0	+	0	+	0	+	0	+	0	+	0	0	+	+	+	4
5) r <sup>r</sup> r	0	+	0	+	+	+	+	0	+	0	0	+	0	0	+	+	+	+	+	+	0	4
6) rr	0	0	0	+	+	+	0	+	0	+	0	+	+	0	+	0	+	+	0	0	+	2
7) R <sub>2</sub> R <sub>2</sub>	+	0	+	+	0	0	+	+	+	+	0	+	+	+	0	0	+	0	+	0	+	4
8) R <sub>1</sub> R <sub>2</sub>	+	+	+	+	+	0	+	0	+	0	0	+	+	0	+	0	+	+	+	+	0	4
9) R <sub>1</sub> r	+	+	0	+	+	+	0	+	0	+	0	+	+	0	+	0	+	+	0	0	+	2
10) R <sub>0</sub> r	+	0	0	+	+	+	+	+	+	+	0	+	0	+	0	0	+	0	+	0	+	3
11) R <sub>0</sub> r	+	0	0	+	+	+	+	0	0	0	0	+	+	0	+	0	+	0	0	+	+	2
Auto																						0√

# Case Review: Multiple Antibody Approach

Choose Smarter!

Run cells that are.....

- **C+**, E-, S-, K-, Jk(b-)
- C-, **E+**, S-, K-, Jk(b-)
- C-, E-, **S+**, K-, Jk(b-)
- C-, E-, S-, **K+**, Jk(b-)
- C-, E-, S-, K-, **Jk(b+)**
- C-, E-, S-, K-, Jk(b-)



# Case Review: Multiple Antibody Approach

	Rh						MNS				LU		P	Lewis		Kell		Duffy		Kidd		PEG
	D	C	E	c	e	f	M	N	S	s	Lu <sup>a</sup>	Lu <sup>b</sup>	P <sub>1</sub>	Le <sup>a</sup>	Le <sup>b</sup>	K	k	Fy <sup>a</sup>	Fy <sup>b</sup>	Jk <sup>a</sup>	Jk <sup>b</sup>	IAT
1	+	+	0	+	+	+	0	+	0	+	0	+	+	0	+	0	+	+	0	+	0	3
2	+	0	+	+	0	0	+	+	0	+	0	+	+	+	0	0	+	0	+	+	0	4
3	0	0	0	+	+	+	+	0	+	0	+	+	0	+	0	+	+	+	+	+	0	2
4	0	0	0	+	+	+	0	+	0	+	0	+	+	0	+	+	+	+	0	+	0	4
5	0	0	0	+	+	+	+	+	0	+	0	+	0	+	0	0	+	0	+	0	+	2
6	+	0	0	+	+	+	+	0	0	0	+	+	0	+	0	+	+	0	0	+	0	0√
Auto																						0√

Run some more select cells and we are done!

# Case Review: Multiple Antibody Approach

Anti-E, anti-C, anti-K, anti-S and anti-Jk<sup>b</sup>

Ensures much faster TAT on results, and provision of blood

Negates the need for specialized testing (efficiency):

- enzyme/chemical treatment of cells
- cell separations
- adsorptions
- trial and error method of selecting cells.

Effective approach for chronically transfused patients

Samples previously sent to a Reference Lab may now be solved in the transfusion service.

***By having the genotyping results available, we are able to work smarter and speed up the antibody identification process dramatically!***





# Case Review: The Unidentified

History of anti-E, anti-K and anti-Fy<sup>a</sup>

Has been transfused since last workup, but not within the past 3 months

Unable to locate compatible blood for cardiac surgery

Request is for 8 units of red cells.

Surgery has been postponed until compatible blood can be provided.

**STAT**

# Case Review: The Unidentified

	Rh						MNS				LU		P	Lewis		Kell		Duffy		Kidd		PEG
	D	C	E	c	e	f	M	N	S	s	Lu <sup>a</sup>	Lu <sup>b</sup>	P <sub>1</sub>	Le <sup>a</sup>	Le <sup>b</sup>	K	k	Fy <sup>a</sup>	Fy <sup>b</sup>	Jk <sup>a</sup>	Jk <sup>b</sup>	IAT
1	+	0	0	+	+	+	+	+	+	0	+	0	+	0	0	+	+	0	+	0	+	1
2	+	0	0	+	+	+	+	0	0	0	+	+	0	+	0	+	+	0	0	+	+	1
3	+	0	0	+	+	+	+	+	+	0	+	0	+	0	0	0	+	0	+	0	+	0√
4	+	0	0	+	+	+	+	0	0	0	+	+	0	+	0	+	+	0	0	+	+	W
Auto																						0√

	Rh						MNS				LU		P	Lewis		Kell		Duffy		Kidd		Ficin
	D	C	E	c	e	f	M	N	S	s	Lu <sup>a</sup>	Lu <sup>b</sup>	P <sub>1</sub>	Le <sup>a</sup>	Le <sup>b</sup>	K	k	Fy <sup>a</sup>	Fy <sup>b</sup>	Jk <sup>a</sup>	Jk <sup>b</sup>	IAT
1	+	0	0	+	+	+	+	+	+	0	+	0	+	0	0	+	+	0	+	0	+	2
2	+	0	0	+	+	+	+	0	0	0	+	+	0	+	0	+	+	0	0	+	+	2
3	+	0	0	+	+	+	+	+	+	0	+	0	+	0	0	0	+	0	+	0	+	0√
4	+	0	0	+	+	+	+	0	0	0	+	+	0	+	0	+	+	0	0	+	+	1
Auto																						0√

# Case Review: The Unidentified



# Case Review: The Unidentified

Time for STAT Genotyping!

## Predicted Phenotype:

- C+E-c+e+
- K-k+ Kp(a-b+) Js(a-b+)
- Fy(a-b+)
- Jk(a+b+)
- M+N-S+s+
- Lu(a-b+)
- Do(a+b-)



# Case Review: The Unidentified

## The Ah-Ha Moment.....

She's already made the E, K, and Fy<sup>a</sup>

Maybe an N? But the pattern doesn't fit.

What about that Do<sup>b</sup>?

- Dombrock status not often on our panel sheets
- Often overlooked specificity

### Predicted Phenotype:

C+E-c+e+

K-k+ Kp(a-b+) Js(a-b+)

Fy(a-b+)

Jk(a+b+)

M+N-S+s+

Lu(a-b+)

Do(a+b-)

# Case Review: The Unidentified

	Rh					MNS				Lutheran		P	Lewis		Kell		Duffy		Kidd		Dombrock		PEG
	D	C	E	c	e	M	N	S	s	Lu <sup>a</sup>	Lu <sup>b</sup>	P <sub>1</sub>	Le <sup>a</sup>	Le <sup>b</sup>	K	k	Fy <sup>a</sup>	Fy <sup>b</sup>	Jk <sup>a</sup>	Jk <sup>b</sup>	Doa	Dob	IAT
1	+	+	0	0	+	+	0	0	+	0	+	+	0	+	0	+	0	+	+	+	0	+	1
2	+	+	0	0	+	+	0	0	+	0	+	+	0	+	0	+	0	+	+	+	0	+	1
3	+	+	0	0	+	+	0	0	+	0	+	+	0	+	0	+	0	+	+	+	0	+	1
4	+	+	0	0	+	+	0	0	+	0	+	+	0	+	0	+	0	+	+	+	+	0	0√
5	+	+	0	0	+	+	0	0	+	0	+	+	0	+	0	+	0	+	+	0	+	0	0√
6	+	+	0	0	+	+	0	0	+	0	+	+	0	+	0	+	0	+	+	+	+	0	0√
Pt																							0√

# Case Review: The Unidentified

Genotyping was able to give us information when serology could not.

- Do<sup>b</sup> antisera is very difficult to come by
- Antisera not commercially available

Difficult to find Do(b-) blood.

Not necessarily due to the antigen frequency (83%)

Red cell Genotyping necessary to identify many Do(b-) donors

8 units of E-, K-, Fy(a-), Do(b-) blood were in inventory and sent to the requesting hospital.

**Turn Around Time for genotyping results are critical in these scenarios.**

# Case Review

**Auto or Allo**



# Case Review: Auto or Allo?

## **Referred to our IRL for investigation of Warm Autoimmune Hemolytic Anemia, and Red Cell Genotyping**

- Patient recently transfused with 4 units of red blood cells
- Hospital policy to obtain a red cell genotype on patients with WAIHA
- Hospital suspects a warm autoantibody present in the patient's serum.
  - Eluate positive with all cells tested
  - No history of alloantibodies.

# Case Review: Auto or Allo?

ABO/RH						
Front Type				Reverse Type		
Anti-A	Anti-B	Anti-A,B	Anti-D	A <sub>1</sub>	A <sub>2</sub>	B
4+	0	4+	4+	0	0	4+

DAT				
Poly	IgG	Anti-C3b,-C3d	Anti-C3d	Control
3+	3+	1	1	0
3+		2	2	0

**Eluate: 3+ with all cells tested**

# Case Review: Auto or Allo?

	Rh						MNS				Lu		P	Lewis		Kell		Duffy		Kidd		Saline		
	D	C	E	c	e	f	M	N	S	s	Lu <sup>a</sup>	Lu <sup>b</sup>	P <sub>1</sub>	Le <sup>a</sup>	Le <sup>b</sup>	K	k	Fy <sup>a</sup>	Fy <sup>b</sup>	Jk <sup>a</sup>	Jk <sup>b</sup>	IS	37C	IAT
1) R <sub>1</sub> R <sub>1</sub>	+	+	0	0	+	0	+	+	+	+	0	+	0	+	0	0	+	0	+	0	+	0	0	3
2) rr	0	0	0	+	+	+	+	0	+	0	+	+ <sup>w</sup>	0	+	+	0	+	+	+	0	0	0	0	4
3) r''r''	0	0	+	+	0	0	0	+	0	+	+	+ <sup>s</sup>	0	+	+	+	+	0	0	+	0	0	0	4
4) R <sub>1</sub> R <sub>1</sub>	+	+	0	0	+	0	+	0	+	+	0	+	0	0	0	+	+	+	+	+	+	0	0	3
5) r''r	0	0	+	+	+	+	+	+	0	+	0	+	0	+	0	+	0	+	0	+	0	0	0	3
6) r'r'	0	+	0	0	+	0	+	+	0	+	0	+	+	0	+	+	+	+	+	+	+	0	0	4
7) R <sub>2</sub> R <sub>2</sub>	+	0	+	+	0	0	+	+	+	0	+	+	+	0	+	0	+	+	0	+	0	0	0	3
AC																						0	0	3

# Case Review: Auto or Allo?

Ficin: 4+ with all cells tested

Alloadsorptions performed on the patient serum since recently transfused

- Anti-K identified in the alloadsorbed serum.



**Warm Auto with underlying anti-K**  
**Now to result the genotyping**

# Case Review: Auto or Allo?

## Red Cell Genotyping Results:

Predicted Phenotype:

- C+E-c+e+
- K-k+ Kp(a+b-) Js(a-b+)
- Fy(a+b-)
- Jk(a-b+)
- M+N-S+s-
- Lu(a-b+)
- Do(a+b+)

**Hold  
Everything!**



# Case Review: Auto or Allo?


## Summary:

- Anti-Kp<sup>b</sup> identified in the patient's serum and eluate.
- Anti-K also in the serum.
- Transfusion reaction! Not WAIHA
- Alloadsorptions always run the risk of removing an antibody to a high frequency antigen.
  - Red Cell Genotyping can reduce this risk




# Identifying Donors using Serology and Red Cell Genotyping

Find a cost effective means to obtain and share information on donors to the transfusion services we serve, in order to decrease their cost while providing the product in the most time efficient manner possible.



# Serologic Screening

## Screened Units Provided



Pk  
↓

**Use diluted Antisera and still get acceptable results.**





# Serologic Screening Results

May 2017 Through Dec 2017					
	Wisconsin	Illinois	Indiana	Michigan	Total
Total Pk Screened	82380	52297	60164	56941	<b>251782</b>
Ro	667	1331	1282	962	4242
R2 (e-)	545	850	979	844	3218
Opos, R1 (c-) 10%	675	438	589	257	1959
AA	233	764	452	454	1903
(O/A)Rh Negative	908	1618	1553	501	4580
Other	0	7	1	2	10
Total Genotyped	3028	5008	4856	3020	<b>15912</b>

# Mass Scale Red Cell Genotyping



---

SmartChip Genotyping

# Mass Scale Red Cell Genotyping

SmartChip MyDesign Chip (5184 nanowells)

384  
Microtiter Plate  
of Samples



384  
Microtiter Plate  
of Assays



Gene Expression  
or  
Genotyping Assays

Dispense Samples


10-30 Minutes

Dispense Assays


10-30 Minutes

Cycle

Gene Expression




Genotyping



# Donor Genotyping Results

VERSITI™



## Predicted Phenotypes

C/c, E/e	Fy <sup>a</sup> /Fy <sup>b</sup>	U, Uvar	Vel
V, VS, hr <sup>B</sup> , hr <sup>S</sup>	Fy(a-b-)	Do <sup>a</sup> /Do <sup>b</sup>	Yt <sup>a</sup> /Yt <sup>b</sup>
K/k	Jk <sup>a</sup> /Jk <sup>b</sup>	Hy	Di <sup>a</sup> /Di <sup>b</sup>
Kp <sup>a</sup> /Kp <sup>b</sup>	M/N	Jo <sup>a</sup>	Co <sup>a</sup> /Co <sup>b</sup>
Js <sup>a</sup> /Js <sup>b</sup>	S/s	Lu <sup>a</sup> /Lu <sup>b</sup>	Cr <sup>a</sup>


RHCE 48	RHCE 697	RHCE 818	RHD 410
RHCE 254	RHCE 712	RHCE 916	
RHCE 340	RHCE 733	RHCE 1006	
RHCE 667	RHCE 748	RHCE 1025	

# Unit sharing among Versiti



National ARDP

Rare/Uncommon units



Ag-neg units

Antigen-negative units  
visible across centers

Data Warehouse



Illinois



Michigan




Indiana



Wisconsin



# How Information Improves Efficiency




# Other Applications

## Weak D/Partial D Typings

AABB and CAP Joint Statement on Phasing-In *RHD* Genotyping for Pregnant Women and Other Females of Childbearing Potential with a Serologic Weak D Phenotype

- *RHD* genotyping is recommended whenever a weak D phenotype is detected by routine Rh blood typing of pregnant women and other females of childbearing potential.





# Other Applications

## Molecular Confirmation of Antigens

- RhCE Variants
- True U Negative vs. U Variant

## “Genotype matching” patients

- Cases of Warm Auto, HTLA, Anti-CD38, unidentified antibodies, STAT, chronically transfused

# What does molecular offer

- Ability to determine a predicted phenotype from a patient sample regardless of transfusion
- Ability to determine a predicted phenotype from a patient sample with a positive DAT
- Gather a large amount of information on a patient or donor when antisera cannot
- Allows us to be more proactive rather than reactive to antibody identification workups
- Can help decrease TAT for patient antibody identification problems and procurement of the appropriate products

# What challenges does molecular face

Genotype does not always reflect phenotype!!!


- Assays may not detect rare nucleotide changes leading to altered or partial antigen expression.
- Null phenotypes may not be detected by some methods.

Availability/Cost:


- Not in many Transfusion Services, not in all Blood Centers
- Becoming more affordable

Requires DNA isolation

- Longer TAT, special techniques, special workflow



# In summary



**The right product....faster**